Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s

Published:2023-06 Issue: Volume:251 Page:109629
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Simmons Ken T.,Chan Joanne,Hussain Sami,Rose Eileen L.,Markham Kate,Byun Tony S.,Panicker Sandip,Parry Graham C.,Storek Michael

Funder

Sanofi

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference38 articles.

1. Complement before molecular biology;Lachmann;Mol. Immunol.,2006

2. Clinical promise of next-generation complement therapeutics;Mastellos;Nat. Rev. Drug Discov.,2019

3. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial;Jäger;Blood.,2019

4. Sutimlimab in cold agglutinin disease;Röth;New Engl. J. Med.,2021

5. First-in-human, healthy volunteer trial of sutimlimab, a humanized antibody for the specific inhibition of the classical complement pathway;Bartko;Clin. Pharmacol. Ther.,2018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial;Expert Opinion on Investigational Drugs;2024-08-22

2. The impact of individual clinical features in cold agglutinin disease: hemolytic versus non-hemolytic symptoms;Expert Review of Hematology;2024-06-28

3. Cold-antibody Autoimmune Hemolytic Anemia: its Association with Neoplastic Disease and Impact on Therapy;Current Oncology Reports;2024-06-14

4. C1s targeting antibodies inhibit the growth of cutaneous squamous carcinoma cells;Scientific Reports;2024-06-12

5. The Complement System as a Therapeutic Target in Retinal Disease;Medicina;2024-06-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3